|
|
home > ict > spring 2020 > comparator sourcing in clinical studies (part two of two) |
 |
 |
PUBLICATIONS |
International Clinical Trials
|
Due to the free movement of trade, European medicinal wholesalers are not obliged to exclusively supply domestic markets and can also export products to foreign clients or sell to sponsors conducting clinical trials. The market is highly volatile with prices and availability of drug product changing frequently. Understanding the rules of trade and commerce is, therefore, a key requisite when dealing with comparator suppliers and their wholesalers in this sector. Although sponsors like to plan drug requirements often over a year in advance, wholesale stock options seldom remain available for longer than a few weeks. Sponsors rarely understand this, assuming that all stock options are being quoted from innovator channels where endless reserves of product are stored in huge warehouses. Avoiding wastage through accurate supply and demand forecasting has now become a critical issue for pharma companies in both clinical trial and commercial settings. This means we are seeing more ‘just-intime’ manufacturing and less stockpiles of comparator drugs available in the wholesale sector. A comparator vendor must have a baseline understanding of pricing and ongoing drug availability in each market and be able to negotiate the right price for the product on the sponsor’s behalf. One essential factor when selecting a comparator supplier is that they have a wide selection of wholesale suppliers – each of whom can supply the same comparator product. In this way, if one or several wholesalers fail to supply, there is always a back-up option in place.
|
Read full article from PDF >>
|
 |
 |
 |
Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | |
|
|
About the author
Toby Watkins is the Founder and Managing Director of a Swiss-based clinical trial supplies consultancy firm, CTSS, that helps sponsors identify, validate, and manage vendor companies across the CTS value chain. Over the last decade, Toby has worked on global comparator sourcing programmes helping sponsors source comparator drugs, ancillaries, and reference products and identify their vendors in over 30 countries around the globe. Prior to entering the clinical arena, he worked on named-patient and managed access programmes in emerging markets. Toby has had the privilege of working with many of the world’s innovators, comparator sourcing companies, CROs, CMOs, biotechs, Big Pharma companies, and their suppliers at every stage of drug development across multiple indications.
toby.watkins@clinicaltrialsupplysolutions.com
|
|
 |
 |
 |
|
 |
News and Press Releases |
 |
Expansion in Hungary: SCHOTT and Hungarian government invest in cutting-edge syringe production
10 March 2022, Lukácsháza, Hungary / Mainz, Germany: In light
of the growing demand for drug delivery solutions, the international
technology group SCHOTT is again investing in its pharma business: The
company is planning to build an entirely new production for high-quality
prefillable glass syringes (PFS) in Hungary.
More info >> |
|

 |
White Papers |
 |
Quality Systems Guide
Research Quality Association
This guide concentrates on the core, underlying principles of quality that are pivotal – explicitly or implicitly – to all quality management standards that impact on research and development.
More info >> |
|
|